Superstring Capital Management LP
- SEC CIK
- 0001931118
- Latest filing
- Aug 14, 2026
Holdings in Q2 2024
Holdings as of Jun 30, 2024, filed Aug 14, 2024. Long positions only; changes compare share counts with Q1 2024.
- Positions
- 39
- +2 vs. Q1 2024
- Portfolio value
- $79.3M
- −$71.9M (−47.5%) vs. Q1 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| SPRBSpruce Biosciences, Inc. | COM | 77,992 | $40.4K | 0.1% | −362,233−82.3% | Reduced | History |
| SYRSSyros Pharmaceuticals, Inc. | COM NEW | 37,789 | $195.0K | 0.2% | +37,789 | New | History |
| CMPSCOMPASS Pathways plc | SPONSORED ADS | 32,497 | $196.3K | 0.2% | +32,497 | New | History |
| Ys Biopharma Co LtdG9845F109 | ORDINARY SHARES | 307,920 | $199.5K | 0.3% | 00.0% | Unchanged | – |
| MRSNMersana Therapeutics, Inc. | COM | 110,073 | $221.2K | 0.3% | +110,073 | New | History |
| MRNSMarinus Pharmaceuticals, Inc. | COM NEW | 261,861 | $306.4K | 0.4% | −303,689−53.7% | Reduced | History |
| EYPTEyePoint, Inc. | COM NEW | 37,838 | $329.2K | 0.4% | +37,838 | New | History |
| KPTIKaryopharm Therapeutics Inc. | COM | 534,485 | $463.7K | 0.6% | +534,485 | New | History |
| PEPGPepGen Inc. | COM | 29,249 | $466.8K | 0.6% | −85,136−74.4% | Reduced | History |
| ATYRaTYR PHARMA INC | COM NEW | 313,028 | $488.3K | 0.6% | +313,028 | New | History |
| ZURAZura Bio Ltd | CLASS A ORD SHS | 156,626 | $548.2K | 0.7% | +156,626 | New | History |
| KURAKura Oncology, Inc. | COM | 36,242 | $746.2K | 0.9% | +36,242 | New | History |
| BMEABiomea Fusion, Inc. | COM | 167,110 | $752.0K | 0.9% | +167,110 | New | History |
| SVRASavara Inc | COM | 200,000 | $806.0K | 1.0% | −1,865,144−90.3% | Reduced | History |
| CATXPerspective Therapeutics, Inc. | COM NEW | 87,638 | $873.8K | 1.1% | +87,638 | New | History |
| ALLKAllakos Inc. | COM | 940,578 | $940.6K | 1.2% | −293,161−23.8% | Reduced | History |
| TNGXTango Therapeutics, Inc. | COM | 115,571 | $991.6K | 1.2% | +115,571 | New | History |
| CABACabaletta Bio, Inc. | COM | 139,895 | $1.05M | 1.3% | −150,902−51.9% | Reduced | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 45,571 | $1.07M | 1.4% | +45,571 | New | History |
| NVCRNovoCure Ltd | ORD SHS | 66,892 | $1.15M | 1.4% | +66,892 | New | History |
| TRMLTourmaline Bio, Inc. | COM | 95,229 | $1.22M | 1.5% | +25,257+36.1% | Added | History |
| NAMSNewAmsterdam Pharma Co N.V. | ORDINARY SHARES | 64,213 | $1.23M | 1.6% | +64,213 | New | History |
| CTMXCytomX Therapeutics, Inc. | COM | 1,151,518 | $1.40M | 1.8% | +472,115+69.5% | Added | History |
| APGEApogee Therapeutics, Inc. | COM | 36,928 | $1.45M | 1.8% | −7,940−17.7% | Reduced | History |
| PYXSPyxis Oncology, Inc. | COMMON STOCK | 484,443 | $1.60M | 2.0% | −9,316−1.9% | Reduced | History |
| ALLOAllogene Therapeutics, Inc. | COM | 689,912 | $1.61M | 2.0% | +168,663+32.4% | Added | History |
| FATEFate Therapeutics Inc | COM | 497,360 | $1.63M | 2.1% | −423,116−46.0% | Reduced | History |
| ONCBeOne Medicines Ltd. | ADR | 12,508 | $1.78M | 2.2% | +12,508 | New | History |
| CRBPCorbus Pharmaceuticals Holdings, Inc. | COM NEW | 56,468 | $2.56M | 3.2% | +56,468 | New | History |
| ARWRArrowhead Pharmaceuticals, Inc. | COM | 111,133 | $2.89M | 3.6% | +111,133 | New | History |
| ACLXArcellx, Inc. | COMMON STOCK | 59,133 | $3.26M | 4.1% | +59,133 | New | History |
| KROSKeros Therapeutics, Inc. | COM | 74,288 | $3.39M | 4.3% | +40,460+119.6% | Added | History |
| ZLABZai Lab Ltd | ADR | 215,178 | $3.73M | 4.7% | +215,178 | New | History |
| NKTXNkarta, Inc. | COM | 875,999 | $5.18M | 6.5% | −313,194−26.3% | Reduced | History |
| ETNB89bio, Inc. | COM | 680,403 | $5.45M | 6.9% | −260,884−27.7% | Reduced | History |
| BBIOBridgeBio Pharma, Inc. | COM | 219,837 | $5.57M | 7.0% | −133,670−37.8% | Reduced | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 956,542 | $6.51M | 8.2% | +956,542 | New | History |
| LEGNLegend Biotech Corp | SPONSORED ADS | 154,665 | $6.85M | 8.6% | +154,665 | New | History |
| CYTKCytokinetics Inc | COM NEW | 187,633 | $10.2M | 12.8% | −91,282−32.7% | Reduced | History |
Sold out since Q1 2024 (19)
Positions held at the end of Q1 2024 that are gone from this filing.
| Security | Class | Shares in Q1 2024 | Value in Q1 2024 | % of portfolio in Q1 2024 | History |
|---|---|---|---|---|---|
| IDYAIDEAYA Biosciences, Inc. | COM | 217,070 | $9.53M | 6.3% | History |
| DAWNDay One Biopharmaceuticals, Inc. | Stock | 349,679 | $5.78M | 3.8% | History |
| ROIVRoivant Sciences Ltd. | SHS | 531,019 | $5.60M | 3.7% | History |
| IONSIonis Pharmaceuticals Inc | COM | 120,896 | $5.24M | 3.5% | History |
| URGNUroGen Pharma Ltd. | COM | 288,267 | $4.32M | 2.9% | History |
| VRNAVerona Pharma plc | SPONSORED ADS | 259,383 | $4.17M | 2.8% | History |
| JBIOJade Biosciences, Inc. | COM | 110,264 | $3.26M | 2.2% | History |
| AXSMAxsome Therapeutics, Inc. | COM | 36,607 | $2.92M | 1.9% | History |
| DYNDyne Therapeutics, Inc. | COM | 99,822 | $2.83M | 1.9% | History |
| PRAXPraxis Precision Medicines, Inc. | COM NEW | 40,119 | $2.45M | 1.6% | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 12,754 | $1.93M | 1.3% | History |
| ANNXAnnexon, Inc. | COM | 155,728 | $1.12M | 0.7% | History |
| Avidity Biosciences, Inc.05370A108 | COM | 37,031 | $945.0K | 0.6% | – |
| LYRALyra Therapeutics, Inc. | COM | 145,284 | $903.7K | 0.6% | History |
| INZYInozyme Pharma, Inc. | COM | 112,739 | $863.6K | 0.6% | History |
| AUPHAurinia Pharmaceuticals Inc. | COM | 98,691 | $494.4K | 0.3% | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 32,025 | $379.8K | 0.3% | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 9,038 | $358.3K | 0.2% | History |
| SYSo-Young International Inc. | SPONSORED ADS | 182,742 | $199.2K | 0.1% | History |